Intellia Therapeutics
NTLA
About: Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Employees: 598
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
63% more call options, than puts
Call options by funds: $18.2M | Put options by funds: $11.2M
30% more capital invested
Capital invested by funds: $720M [Q1] → $934M (+$214M) [Q2]
25% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 87
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
1.74% less ownership
Funds ownership: 97.81% [Q1] → 96.07% (-1.74%) [Q2]
5% less funds holding
Funds holding: 291 [Q1] → 275 (-16) [Q2]
23% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 52
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
|
Chardan Capital
Geulah Livshits
|
$60
|
Buy
Maintained
|
11 Aug 2025 |
|
RBC Capital
Luca Issi
|
$21
|
Outperform
Maintained
|
8 Aug 2025 |
|
Wells Fargo
Yanan Zhu
|
$45
|
Overweight
Maintained
|
8 Aug 2025 |
|
HC Wainwright & Co.
Mitchell S. Kapoor
|
$25
|
Buy
Maintained
|
8 Aug 2025 |
Financial journalist opinion
Based on 4 articles about NTLA published over the past 30 days
